Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP): IP Portfolio, Licensing and R&D are Keys to Growth in 2018

  • LXRP has global patents or patents-pending in more than 40 countries, including the U.S., Australia, China, the European Union and Canada
  • Company is working through a C$250,000 budget for an 18-month collaborative research agreement with the National Research Council
  • Licensing is a revenue generator, with LXRP offering to license its disruptive DehydraTECH™ technology in countries where it is patented or patent-pending

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is generating revenue and knowledge through both licensing of its IP portfolio and advancement of R&D projects. It already has patents and multiple patents-pending in more than 40 countries. It has received patent approvals in the U.S. and Australia for its DehydraTECH™ delivery technology (http://cnw.fm/WIdR3). Some patent applications have already reached the active patent investigation phase in China, the European Union and Canada.

LXRP is a technology disruptor for delivery of edible forms of cannabinoids. This Kelowna, British Columbia-based food bioscience company has developed a high absorption hemp oil formula, protein energy bars, exotic teas and coffee, beer and soft drinks, and capsules and mouth-melts. All of these products share qualities of high absorption and radically improved taste, as compared to other cannabis-related food products.

The Canadian Institutes of Health Research has secured $1.4 million in funding for Canadian cannabis research projects (http://cnw.fm/DeM9h). That will fund research ranging from the potential impacts of cannabis on driving, pregnancy, childhood health, youth mental health, indigenous populations and workplace health and safety (http://cnw.fm/gTE4r).

LXRP itself has signed a C$250,000 collaborative research agreement with the National Research Council (“NRC”) for an 18-month period to investigate opportunities and determine the best methods for processing lipophilic active agents within foods.

Licensing its intellectual property portfolio is a core revenue generation strategy for LXRP (http://cnw.fm/pmF79). For example, the company’s disruptive new DehydraTECH technology is available to be licensed in areas including processed foods, supplements, vitamins, drugs and cannabinoids. To prospective licensees, LXRP can eventually transition to a definitive fee for a structure agreement between itself and a new licensee.

The company makes its technology available on either a semi-exclusive or exclusive access basis that defines licensing by geographic region(s), for a set period of time and limited to specific product categories. LXRP has suggested that it will license DehydraTECH in any of the more than 40 countries globally where it is patented or patent-pending.

For more information, visit the company’s website at www.LexariaBioscience.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

w

Connecting to %s